What Is the LRND ETF? A Complete Guide to Returns, Expense Ratio, Holdings, and Alternative ETFs
The NYLI U.S. Large Cap R&D Leaders ETF (LRND) is a passive fund that selects U.S. large-cap innovative companies with high R&D investment relative to sales, and its R&D-based selection methodology and weighting differences versus QQQ, VUG, and MTUM are the core selection criteria.
What Is the NYLI U.S. Large Cap R&D Leaders ETF?
It is a passive ETF that selects and overweights U.S. large-cap innovation-leading companies with high R&D investment relative to sales. By focusing on R&D-driven companies, it provides exposure to long-term growth potential.
It is well-suited for growth-oriented investors who want exposure to innovation-driven large-caps while accepting growth-stock volatility.
The ETF is managed by NYLI on a passive (index-tracking) basis.
How Does the NYLI U.S. Large Cap R&D Leaders ETF Work?
| Item | Details |
|---|---|
| Investment Target | U.S. large-cap R&D leaders |
| Management Style | Passive (R&D-based selection) |
| Selection Criteria | R&D investment scale |
| Dividend Frequency | Quarterly |
| Total Expense Ratio | 0.14% |
It tracks an index that selects and overweights U.S. large-cap companies with high R&D investment relative to sales. Unlike simple market-cap weighting, it uses an R&D-driven rule-based methodology to focus on innovation leaders, providing exposure to companies with strong long-term growth drivers.
- Stock selection based on R&D investment criteria
- Concentration in innovation-leading large-caps
NYLI U.S. Large Cap R&D Leaders ETF Size and Cost (AUM · Expense Ratio)
Assets under management (AUM) stand at $400.6M, and the total expense ratio is 0.14% annually.
The main point of comparison versus plain market-cap-weighted large-cap ETFs is the R&D-based selection methodology.
I'm sorry, but it looks like the sentence you wanted me to rewrite got cut off—it ends abruptly at "U.S." with no closing tag or further text. Could you please paste the full sentence? Once I have the complete text, I'll be happy to rewrite it in pure natural English while keeping all numbers, tickers, and placeholders intact. Large Cap R&D Leaders ETF Performance and FlowsR&D-leading large-caps carry heavy weights in technology and healthcare, making them highly sensitive to interest rates, growth expectations, and earnings season. They tend to outperform during growth-favored regimes and underperform when rates rise or value stocks are in favor. Because the portfolio is rule-based, performance can diverge from market-cap indices.
R&D leaders see flows shift with risk appetite, rate outlook, and innovation-theme momentum, and capital may rotate into this product group when interest in innovation such as artificial intelligence rises. Performance differences driven by rates and style rotation should also be monitored.
NYLI U.S. Large Cap R&D Leaders ETF Strengths and Weaknesses
Exposure to R&D leaders is the core strength, while growth-stock volatility, sector concentration, and tracking difference are key considerations.
💪 Key Strengths
⚠️ Points to Watch
NYLI U.S. Large Cap R&D Leaders ETF Alternative ETFs and Related Products
For simpler Nasdaq 100 growth exposure, QQQ is a direct substitute, while VUG is a comparable option for broad large-cap growth exposure. Investors seeking a momentum tilt may also consider MTUM alongside this ETF. The key differentiator is that this ETF selects innovation-leading large-caps based on R&D investment, giving it a stronger innovation profile than plain market-cap indices.
Investor Checklist for the NYLI U.S. Large Cap R&D Leaders ETF
Here are the points to review before investing in LRND. While R&D-leader exposure is appealing, growth-stock volatility, sector concentration, and tracking difference should be checked in advance. It is also wise to compare it with plain large-cap growth products.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 🔬 R&D Selection | Review R&D investment criteria | R&D-based |
| 📈 Growth Exposure | Review innovation-leader large-cap composition | Growth-oriented |
| 🧩 Sector Concentration | Review technology and healthcare tilt | Possible tilt |
| 💵 Expense Ratio | Confirm R&D-selection ETF expense ratio | Needs review |
Rising rates, growth-stock weakness, and technology and healthcare concentration are the main drivers of long-term performance, and the R&D-based selection can lead to a composition different from market-cap indices. The heavy growth tilt can result in sharp drawdowns during broad market sell-offs.
It is a suitable candidate for growth-oriented investors seeking exposure to R&D-driven innovation large-caps. If plain large-cap growth exposure is the priority, products such as QQQ and VUG should be considered, while those prioritizing R&D-based selection should compare this product as well.
NYLI U.S. Large Cap R&D Leaders ETF Strengths and Weaknesses
Exposure to R&D leaders is the core strength, while growth-stock volatility, sector concentration, and tracking difference are key considerations.
💪 Key Strengths
⚠️ Points to Watch
NYLI U.S. Large Cap R&D Leaders ETF Alternative ETFs and Related Products
For simpler Nasdaq 100 growth exposure, QQQ is a direct substitute, while VUG is a comparable option for broad large-cap growth exposure. Investors seeking a momentum tilt may also consider MTUM alongside this ETF. The key differentiator is that this ETF selects innovation-leading large-caps based on R&D investment, giving it a stronger innovation profile than plain market-cap indices.
| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
| Schwab Fundamental U.S. Large Company ETF | $30.78 | -1.7% | $27.4B | 0.25% | 1.53% | +18.9% | |
| Invesco RAFI US 1000 ETF | $52.77 | -1.8% | $9.7B | 0.34% | 1.4% | +18.6% | |
| Schwab Fundamental U.S. Small Company ETF | $33.85 | -2.3% | $8.6B | 0.25% | 1.31% | +15.4% | |
| John Hancock Multifactor Mid Cap ETF | $69.05 | -2.4% | $5.9B | 0.41% | 0.95% | +11.3% | |
| Columbia Research Enhanced Core ETF | $40.88 | -3.2% | $5.8B | 0.15% | 0.79% | +4.3% |
| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
| NVDA | NVIDIA Corp | 0.31% | $125.53 | -14.0% | $3.03T | 13.5 | 0.63% |
| GOOGL | Alphabet Inc | 0.24% | $265.29 | -2.7% | $3.23T | 13.8 | 0.33% |
| AAPL | Apple Inc | 0.22% | $342.56 | -1.9% | $4.98T | 38.2 | 0.33% |
| MSFT | Microsoft Corp | 0.15% | $484.52 | -2.8% | $3.60T | 25.3 | 0.81% |
| AVGO | Broadcom Inc | 0.07% | $304.41 | -12.2% | $1.45T | 38.9 | 0.86% |
| LLY | Lilly(Eli) & Co | 0.05% | $1347.11 | -0.3% | $1.27T | 44.3 | 0.51% |
Investor Checklist for the NYLI U.S. Large Cap R&D Leaders ETF
Here are the points to review before investing in LRND. While R&D-leader exposure is appealing, growth-stock volatility, sector concentration, and tracking difference should be checked in advance. It is also wise to compare it with plain large-cap growth products.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 🔬 R&D Selection | Review R&D investment criteria | R&D-based |
| 📈 Growth Exposure | Review innovation-leader large-cap composition | Growth-oriented |
| 🧩 Sector Concentration | Review technology and healthcare tilt | Possible tilt |
| 💵 Expense Ratio | Confirm R&D-selection ETF expense ratio | Needs review |
Rising rates, growth-stock weakness, and technology and healthcare concentration are the main drivers of long-term performance, and the R&D-based selection can lead to a composition different from market-cap indices. The heavy growth tilt can result in sharp drawdowns during broad market sell-offs.
It is a suitable candidate for growth-oriented investors seeking exposure to R&D-driven innovation large-caps. If plain large-cap growth exposure is the priority, products such as QQQ and VUG should be considered, while those prioritizing R&D-based selection should compare this product as well.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
This article reflects information as of June 10, 2026.